The pivotal studies, Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization (CNV) in nAMD (ANCHOR)[1, 2] and Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of nAMD (MARINA)[3], were the first randomised phase 3 clinical trials to demonstrate that monthly administration of 0.3 mg and 0.5 mg ranibizumab not only prevented vision loss associated with nAMD, but also improved mean visual acuity between 7.2 and 10.7 letters according to the Early Treatment Diabetic Retinopathy Study (ETDRS) over 2 years. Here, VEGFA is linked to diabetic retinopathy.